Valencia

• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended recruitment
  2024-510719-31-00 5 2025-01-24 Moderate to Severe Vasomotor Symptoms (VMS)
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended recruitment
  2024-514228-18-00 4 2025-01-16 Asthma in adults who remain uncontrolled despite medium to high dose I
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien … Ended recruitment
  2023-504420-26-00 4 2025-01-13 Bladder Cancer
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended recruitment
  2024-511933-36-00 4 2025-01-02 Diffuse cutaneous systemic sclerosis (dcSSc)
• Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended recruitment
  2024-513952-13-00 5 2025-01-02 HR+ / HER2- advanced breast cancer
• Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t … Ended recruitment
  2024-514728-17-00 11 2024-12-30 Advanced or recurrent endometrial cancer
• A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended recruitment
  2024-512066-33-00 6 2024-12-19 Haemophilia A
• A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) ( … Ended recruitment
  2024-514283-40-00 4 2024-12-19 Pulmonary Hypertension
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended recruitment
  2024-511881-35-00 5 2024-12-17 Prurigo Nodularis
• Preemptive treatment with venetoclax plus azacitidine in patients diagnosed with acute myeloid leukemia (AML) with persistence or reappearan … Ended recruitment
  2024-510648-29-00 10 2024-12-12 Patients diagnosed with acute myeloid leukemia (AML) with persistent m
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dy … Ended recruitment
  2024-512828-12-00 6 2024-12-05 Duchenne Muscular Dystrophy
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W … Ended recruitment
  2023-505110-14-00 4 2024-12-02 Colorectal Cancer
• A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy Ended recruitment
  2023-508891-12-00 4 2024-11-28 Diabetic retinopathy
• Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended recruitment
  2023-507270-41-00 4 2024-11-22 Advanced or Metastatic Non-small Cell Lung Cancer
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub … Ended recruitment
  2024-511482-11-00 5 2024-11-20 Dry Age-Related Macular Degeneration (Dry AMD)
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended recruitment
  2023-508073-87-00 7 2024-11-14 Advance solid tumors harboring the KRAS G12C mutation
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended recruitment
  2023-510341-19-00 5 2024-11-14 acne vulgaris

Showing 937–960 of 1,853 trials